RNS Number : 2289L
Transense Technologies PLC
07 July 2026

7 July 2026

Transense Technologies plc

("Transense" or the "Company"**)**

Board Changes

Retirement of Chief Financial Officer and Appointment of Finance Director (designate)

Transense Technologies plc (AIM: TRT), the provider of specialist sensor technology and measurement solutions, announces that Melvyn Segal has informed the Board of his intention to retire from the role of Chief Financial Officer ("CFO") and Company Secretary with effect from the Company's Annual General Meeting (AGM) in November 2026. The Board also announces the appointment of Richard Michael Pearce ACA as Finance Director with effect from 1 September 2026.

Melvyn will remain with the Company in an executive capacity for a handover period until the AGM, and will subsequently remain on the Board as a non-executive director for a further year. The Board would like to thank Melvyn for his significant contribution to Transense over many years, during which the Company and its prospects have been transformed.

Richard brings over twenty years of financial, commercial and listed company experience to Transense. Since qualifying as a Chartered Accountant with Ernst & Young in 1999, he has held senior finance roles at GE Healthcare and TD Williamson, and most recently as Finance Director at Lombard Medical where he oversaw a scale-up in revenues from £6m to £25m per annum since 2018. He will initially work alongside Melvyn in a non-board role as Finance Director, with progression to the Board leading the Group's finance function when Melvyn's steps down as CFO in November 2026.

The Board welcomes Richard to his new role and we look forward to his contribution to delivery of the future growth strategy.

For further information please visit www.transense.com or contact:

Transense Technologies plc	Via Investor Relations
Nigel Rogers (Executive Chairman)	(see below)
Ryan Maughan (Managing Director)	
Melvyn Segal (Chief Financial Officer)	
Cavendish Capital Market Limited (Nominated Adviser and Broker)	0207 220 0500
Adrian Hadden / Callum Davidson (Corporate Finance)	
Jasper Berry (Sales)	
Investor Relations	Tel: +44 (0)1869 238380
Anice McNamee	Investor.relations@transense.co.uk

Notes to Editors:

Transense is headquartered in Oxfordshire, UK and its shares are traded on AIM, a market operated by the London Stock Exchange (AIM: TRT). The Company develops and supplies advanced sensor technology and measurement solutions used by some of the world's leading companies to improve performance, efficiency, and safety in demanding, mission critical applications. Transense currently operates through two active business segments:

- SAWsense - designs, supplies and licences advanced sensor solutions based on proven, patent protected Surface Acoustic Wave (SAW) technology to world leading companies in aerospace, automotive, and industrial machinery (including robotics), enabling improved efficiency and performance of their products. Key customers include GE Aerospace, Parker Meggitt, McLaren Applied, Airbus and several other confidential Tier One automotive, aerospace and industrial machinery suppliers.

- Translogik - develops smart, connected commercial vehicle tyre inspection equipment to many of the world's leading tyre suppliers, fleet operators and service centres. Enabling accurate measurement and digital capture of safety-critical tyre condition data, used to reduce operating costs, improve safety and provide audit records for regulatory compliance. Key customers include Bridgestone, Goodyear, Continental and Prometeon (Pirelli), and leading independent providers of vehicle fleet maintenance management software.

In addition, Transense earns residual royalty income from Bridgestone iTrack - a tyre monitoring system for off-highway vehicles that was developed by Translogik. The associated sales, support and development infrastructure were sold to Bridgestone Corporation, the world's largest tyre producer, in June 2020, and the intellectual property was licensed exclusively to Bridgestone under a ten-year deal expiring in 2030.

Find out more at: https://www.transense.com/

END

BOAAKABQCBKDDOK